KADUNA TARGETS ₦120BN IGR IN 2026 — KADIRS CHAIRMAN. (PHOTO).

Image
 Kaduna Targets ₦120bn IGR In 2026 — KADIRS Chairman   Kaduna State has set an Internally Generated Revenue (IGR) target of ₦120 billion for the 2026 fiscal year, with the Kaduna State Internal Revenue Service (KADIRS) expected to play a central role in achieving the target. The Executive Chairman of KADIRS, Jerry Adams, FCTI, FNIM, FCE, CNA, disclosed this during the Service’s Annual Performance Review, Work Plan, and Strategic Retreat.  He explained that although the state government approved ₦74 billion as KADIRS’ official revenue target, the Service raised its internal benchmark to ₦80.09 billion to motivate staff to exceed expectations. He further stated that the proposed 2026 budget by the Kaduna State Planning and Budget Commission stands at ₦117.28 billion, with KADIRS expected to generate ₦74.28 billion, while Ministries, Departments, and Agencies (MDAs) are projected to generate ₦43.24 billion. According to Adams, the retreat was convened to strengthen implement...

CHINESE COVID-19 VACCINE SHOWS PROMISING RESULTS.[PHOTO}.

Chinese COVID-19 vaccine shows promising results - CGTN
   We are all expecting a COVID-19 vaccine that could possibly end the pandemic that has killed more than 330,000 people.
Now the first vaccine candidate from China has finished its phase-1 trial on humans, and the results have been put online for everyone to examine.
The Lancet, a respected medical journal in the UK, published the results on Friday saying it is "safe" and "induces rapid immune response."
The research injected the potential vaccine into 108 volunteers.
They were divided into three groups, each taking a different dose of the vaccine.
The vaccine, classified as "recombinant adenovirus type-5 vectored" (Ad5-nCoV), acts as a natural infection and is especially good at teaching the immune system how to fight the virus.During the next 28 days, no serious reactions were found, meaning the vaccine seemed to be tolerable by humans.Also, antibodies against the SARS-CoV-2 started to surge two weeks after the injection and reached its peak on day 28.The vaccine "warrants further investigation," the paper on The Lancet concluded.A phase-2 clinical trial has started with 508 volunteers involved.The trial was conducted by a team led by Chen Wei, a biology professor from Academy of Military Medical Sciences and a member of the Chinese Academy of Engineering.There are other two vaccines allowed for human trials in China. They are ShaCoVacc and PiCoVacc.-CCTV.
Chinese COVID-19 vaccine shows promising results - CGTN

Comments

Popular posts from this blog

SHAKIRA COVERS WOMEN'S HEALTH MAGAZINE,APRIL ISSUE.

INNOSON GIVES OUT BRAND NEW IVM G5 AND SALARY FOR LIFE TO THE MAN WHO PROPHESIED ABOUT HIS VEHICLE MANUFACTURING IN 1979.(PHOTO).

THE NEW OONI OF ILE-IFE,WILL NOT EAT THE HEART OF THE LATE OONI-PALACE CHIEFS.